Please select the most similar patent number from A, B, C and D. Which number is?
Provided is an adipose tissue preservation solution, comprising: polyethylene glycol 400, human albumin, norfloxacin, low molecular dextran, and Ac-DEVD-CHO. The present invention uses the polyethylene glycol 400 as a base component for the first time; said substance has good compatibility with an oil-type substance, and may also separate out a lipid-type substance after being compatible with a water-type substance; and human albumin is used as a nutritional component of adipose mesenchymal stem cell preservation solution. In addition, an added apoptosis inhibitor may greatly improve the stress resistance of a cell and maintain cell viability, such that adipose tissue under the condition of in vitro and long-term transportation can still ensure that an adipose stem cell maintains the original cell morphology and biological characteristics. Meanwhile, the preparation method for a cell tissue preservation solution provided is simple, and the viability of an adipose mesenchymal stem cell may still be maintained very well within 72 hours.
A: Provided in the present invention are a mesenchymal stem cell injection, a preparation method thereof and the use in preparing drugs for treatingdilated cardiomyopathy in children. The mesenchymal stem cells used in the present invention are derived from human umbilical cord and placenta, and the mesenchymal stem cell injection contains 2×10 5 -1×10 7  mesenchymal stem cells/ml, clinical-grade DMSO at a volume ratio of 5%-8%, human albumin at a mass-to-volume ratio of 1%-6% and a compound electrolyte solution.
B: The present invention provides a mesenchymal stem cell injection, a preparation method thereof, and application thereof in preparing a drug for treating ulcerative colitis. The mesenchymal stem cell injection comprises the following ingredients: mesenchymal stem cells of 2×10 5 -1×10 7 /ml; DMSO with the volume ratio being 5-10%; human serum albumin with the mass-to-volume ratio being 1-6%; and 1% of low molecular dextran and a compound electrolyte solution.
C: Provided in the present invention is a cell freezing medium for clinical use. In particular, the cell freezing medium of the present invention comprises the following components: (1) human albumin; (2) a cryoprotectant, wherein the cryoprotectant comprises a combination of one or more of dimethyl sulfoxide, glycerol and ethylene glycol; (3) a saline buffer, wherein the saline buffer is a solution comprising ions Na+, K+, Mg+, Cl- and CH3COO-; (4) a vitamin; and (5) an amino acid, wherein the concentration of the human albumin is 1-20% (w/v). The cell, after long-term cryopreservation with the freezing medium of the present invention, has a high viability, and the cellular efficiency maintains a high uniformity. The grade of purity of the freezing medium of the present invention is the pharmaceutical grade or USP grade; and the freezing medium is safe and reliable for clinical use, and can be used for conventional adherent and suspension cells.
D: The present invention provides a mesenchymal stem cell injection, a preparation method thereof, and application thereof in preparing a diabetes drug. Mesenchymal stem cell used by the present invention come from the human umbilical cord and the human placenta. The ingredients of the mesenchymal stem cell injection are: mesenchymal stem cells, human serum albumin, low molecular weight heparin, a compound amino acid, vitamin C, and a solution medium. The solution medium is a compound electrolyte solution, glucose water, or a normal saline solution.
Answer: C